A Swollen Finger That Won't Let Him Work the Register
His swollen finger and heel pain haven't budged on his first biologic, and four different drug classes are all equally reasonable next steps by the numbers. What actually settles it is something in his own history none of those numbers capture.
Otis G. has owned the same hardware store for twenty-two years and spends most of his weekends restoring old lawn tractors in the shop behind it, which is how he first noticed his right index finger had swollen into what he called "a little sausage" rather than a joint. That dactylitis, alongside pain at both Achilles insertions bad enough to keep him off a ladder, was diagnosed as psoriatic arthritis a year ago and treated with adalimumab for the past seven months — a drug that has done essentially nothing for either finding. His finger is still swollen, both heels still hurt first thing in the morning and after standing behind the register all day, and his LEEDS enthesitis score hasn't moved.
The domain he actually needs treated — enthesitis and dactylitis, not the polyarticular synovitis PsA more commonly presents with — happens to be one where GRAPPA names an unusually wide field of equally strongly recommended options: TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, JAK inhibitors, and PDE4 inhibitors are all listed without a ranking among them for this specific domain. Since his first TNF inhibitor already failed him, that leaves four mechanistically distinct alternatives on paper, all guideline-equal for exactly his presentation. What breaks that tie is a detail that has nothing to do with enthesitis biology at all: seven years ago, before his psoriatic arthritis was ever diagnosed, Otis was treated for a bout of latent tuberculosis reactivated during a brief course of infliximab for a different inflammatory condition, successfully completed a full antituberculous regimen, and has been TB-negative on repeat testing since — a history that makes any biologic carrying real reactivation risk a conversation his rheumatologist wants to have explicitly rather than assume is closed. Otis remembers that reactivation clearly enough — six weeks in an isolation room, missed store hours his brother covered — that he raised it himself before anyone on today's team had finished reviewing his chart, and said directly that he'd rather take a somewhat less potent drug than relive that particular six weeks.
Four guideline-equal options, one disqualifying detail
I don't want to treat his TB history as a footnote just because his adalimumab failure this time was about efficacy, not infection. He's had a real reactivation event on a TNF inhibitor. Given four guideline-equal mechanisms on the table for his enthesitis and dactylitis, I'd rather steer away from biologic immunosuppression of any kind for him specifically and reach for apremilast, which doesn't carry that risk profile at all.
I'd support that instinct directly on the infectious-disease side. PDE4 inhibition works through an entirely different mechanism, intracellular cyclic-AMP signaling, not broad immune suppression — it carries essentially no meaningful TB reactivation signal in the literature. For a patient with his specific history, that's a genuinely clean safety margin, not just a smaller risk than the alternatives.
I recognize apremilast is generally considered less potent for enthesitis than the biologic options on this list, and I don't think infection risk alone should override that efficacy gap without at least naming it plainly to him.
I'd push back gently on treating this as "any biologic versus none." His reactivation happened specifically on infliximab, a TNF inhibitor — and TB reactivation risk is not uniform across biologic classes. IL-17 and IL-23 inhibitors carry real but substantially smaller reactivation signals than TNF blockade in the literature. Given how much more effective the biologic options generally are for enthesitis than apremilast, I think it's fair to have an honest conversation with him about that smaller, real, but genuinely different risk — and let him weigh it directly rather than deciding for him that anything biologic is off the table.
Agreed: repeat TB screening, then start secukinumab, with the choice made explicitly by Otis after a direct discussion of the class-specific reactivation-risk difference between IL-17 inhibition and the TNF inhibitor on which he reactivated years earlier.
Not agreed: whether the group should have led with apremilast regardless of his own stated preference, given his infectious history. The rheumatologist and infectious disease physician remain more cautious about biologic therapy of any kind for him going forward and would revisit apremilast quickly at the first sign of any infectious concern; the clinical pharmacologist views the current plan as the right balance and would not treat a switch to apremilast as automatic.